• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates
Home » Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

Pavmed gains FDA breakthrough nod for esophageal pre-cancer test

February 27, 2020 By Nancy Crotti

PavmedPavmed updated logo (NSDQ:PAVM) recently announced that its Lucid Diagnostics subsidiary has received FDA breakthrough device designation for its EsoGuard esophageal DNA test.

The test uses esophageal samples collected using Lucid’s 510(k)-cleared EsoCheck cell collection device from certain patients at elevated risk for esophageal dysplasia due to chronic gastroesophageal reflux disease (GERD). EsoGuard and EsoCheck are designed to facilitate the diagnosis of Barrett’s esophagus with and without dysplasia — a progression of precursor conditions that culminate in highly lethal esophageal cancer (EAC)— as well as EAC itself, in patients with chronic heartburn.

Although the American College of Gastroenterology (ACG) practice guidelines recommend screening in millions of high-risk patients to detect and treat Barrett’s esophagus, fewer than 10% actually undergo screening using the traditional invasive approach, upper endoscopy, according to PAVmed. Most patients diagnosed with EAC are either unaware of their underlying Barrett’s esophagus or of their missed opportunity to undergo treatment following an earlier diagnosis, the company added.

As a result, more than 80% die within five years of diagnosis. PAVmed estimated a minimum $2 billion immediately addressable domestic market opportunity for EsoGuard at at least $2 billion, based on clinical testing guidelines.

EsoGuard sequences bisulfite-converted DNA to detect methylation at 31 sites on two genes (VIM and CCNA1). It has been shown in a 408-patient human study published in Science Translational Medicine to be highly accurate at detecting BE, with and without dysplasia, as well as EAC, with greater than 90% sensitivity and specificity.

EsoGuard, which is already commercially available as a laboratory-developed test, is the subject of two Lucid-sponsored international multi-center IVD clinical trials in support of an FDA PMA. The screening study will enroll GERD patients without a prior diagnosis of Barrett’s esophagus or EAC who satisfy clinical screening guidelines. The case control study will enroll patients previously diagnosed with Barrett’s esophagus or EAC. In both studies, EsoGuard will be compared to the gold standard of endoscopy with biopsies. Both studies will begin enrolling patients in the coming weeks at 60 sites in the U.S. and Europe.

“EsoGuard’s FDA breakthrough device designation represents a major milestone for PAVmed and Lucid,” said Dr. Lishan Aklog, PAVmed’s chairman and CEO and Lucid’s executive chairman. “This designation validates our belief that EsoGuard is a groundbreaking technology that has the potential to have as great an impact on esophageal cancer as widespread Pap screening has had in preventing deaths from cervical cancer. We look forward to working closely with the FDA to advance our EsoGuard in-vitro diagnostic (IVD) clinical development program at an expedited pace.”

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Oncology Tagged With: FDA, Pavmed

In case you missed it

  • House committee investigates $70M federal contract for AutoMedx ventilators
  • Edwards Lifesciences misses on earnings in Q4
  • COVID-19 assays sales power Hologic to Street-beating Q1
  • Stryker beats the Street on earnings but misses on revenue in Q4
  • How CGMs can inspire lifestyle changes
  • Johnson & Johnson gearing up for COVID-19 vaccine data announcement
  • Sanofi to provide COVID-19 vaccine manufacturing for rival Pfizer
  • Adapting to Pharma’s Next Normal – 2021 Pharmaceutical Trends
  • COVID-19 test sales boost Abbott in Street-beating Q4
  • Varian posts mixed bag Q1 results, expects Siemens Healthineers takeover to complete in early 2021
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
  • Titan Medical closes on $11.5M offering
  • GE ticks up on mixed-bag Q4
  • BD CEO Polen to also serve as board chair
  • Moderna details ‘proactive’ strategy to fight emerging COVID-19 variants  
  • Surmodics’ DCB shown non-inferior to Medtronic’s In.Pact Admiral
  • Longeviti Neuro Solutions ClearFit implant wins FDA clearance for use in ultrasound

RSS From Medical Design & Outsourcing

  • House committee investigates $70M federal contract for AutoMedx ventilators
    A Congressional committee has launched an investigation into a $70 million White House contract for ventilators that reportedly are inadequate to treat people with COVID-19. The Department of Defense signed a $16.2 million contract in spring 2020 to buy SAVe II ventilators, manufactured by AutoMedx (Addison, Tex.), from the supplier Combat Medical Systems, according to… […]
  • How CGMs can inspire lifestyle changes
    As an early adopter of fitness trackers such as the Fitbit, I’ve long appreciated the power of health data. But my recent experience with a continuous glucose monitor (CGM) has done far more to inspire me to look after my health — even as a nondiabetic. I had heard about the potential of such technology… […]
  • COVID-19 mask factory opens in N.J.
    Hudson Holdings Group today announced it has opened a factory to make up to tens of millions of protective masks a month. The Piscataway, N.J., site will produce more than 200 jobs, according to the company, which is in partnership on the project with the State of New Jersey. “Our ultimate goal is to help,”… […]
  • TE Connectivity posts Street-beating Q1 results, medical sales dip 12%
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus on Wall Street. The Schaffhausen, Switzerland-based company reported profits of $381 million, or $1.13 per share, on sales of $3.5 billion for the three months ended Dec. 31, 2020, for a bottom-line gain of 1365.4% sales growth of 11.2% compared with Q1 2020. Adjusted to… […]
  • Could this 3-D printed ‘biomesh’ minimize hernia repair complications?
    Some hernia mesh implants have been associated with adverse post-surgical complications. So researchers at Baylor College of Medicine have developed a 3D-printed biomesh to support and reinforce the damaged abdominal wall and facilitate the healing process. Mesh implants may fail because they promote the adhesion of the intestine, liver or other visceral organs to the… […]
  • Superior Sensor Technology launches versatile differential pressure sensors
    Superior Sensor Technology (Santa Clara, Calif.) today announced the launch of differential pressure sensors for industrial applications that support up to seven selectable pressure ranges in one device. Designed for a wide range of applications, the new ND Series sensors support pressure ranges as low as 62.5 Pa/0.25” H2O to as high as 345 mBar/5… […]
  • BD touts study of antigen test over molecular test for identifying infectious COVID-19 cases
    Becton Dickinson (BD) is touting the results of a small, in-house study of its Veritor Plus antigen test over molecular (PCR) tests to indicate whether an infected person is more likely able to spread SARS-CoV-2. The peer-reviewed study compared antigen and PCR test results to positive results using a viral cell culture test. Viral growth… […]
  • TDK adds pressure sensors for ventilators
    TDK Corporation announced the launch of a new range of differential pressure sensors designed as printed circuit boards for use in medical devices. The sensors are designed for measurement ranges of 16 mbar full-scale (FS), 100 mbar FS and 7 bar FS, with accuracy of up to ±1% FS at temperatures from -20 °C to… […]
  • Pediatric device workshop scheduled for February
    A virtual public meeting on pediatric medical device development is scheduled for Feb. 9-11, 2021. Sponsors include the FDA, AdvaMed, the American Academy of Pediatrics and the Critical Path Institute, a public-private partnership that receives FDA funding. The System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) Virtual Workshop will focus on the… […]
  • Pedra wins breakthrough nod for perfusion system
    Singapore-based Pedra Technology announced today that the FDA has granted the company breakthrough device designation for the periprocedural use of its Xauron perfusion system in the treatment of critical limb-threatening ischemia (CLTI). CLTI is a severe form of peripheral artery disease (PAD) that is defined as ischemic rest pain, tissue loss or gangrene (tissue death) that… […]
  • Freudenberg Medical expands U.S. molding operations
    Freudenberg Medical announced that it has expanded injection molding operations at its Baldwin Park, Calif., operation, which is focused on thermoplastics. Freudenberg Medical Baldwin Park has added six injection molding machines including three new Arburg molding machines, a work cell for two-shot molding and a Wittmann Battenfeld micro-molding machine with in-process visual inspection capability. The… […]

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS